NASDAQ
5.81USD
-0.39 (-6.29%)
We have scored 9 news catalysts on Candel Therapeutics, Inc. (CADL) over the past 12 months. The biggest single-day move next to one of them came Nov 16, 2026, when CADL closed −6.3%: “NeuroPace Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into NeuroPace (NPCE)”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
455.8M
P/E
—
EPS
—
Beta
-0.47
52W range
4.35-14
Day range
5.72–6.23
Open
5.94
Prev close
6.20
Volume
3.3M
Avg volume
1.2M
Dividend
0.00
IPO
2021-07-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Candel Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CADL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.